Plné znění - 47/2014 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod - Mezinárodní standard) Mezinárodní úmluvy proti dopingu ve sportu

47/2014 Sb. m. s.

Sdělení

INFORMACE

47

XXXXXXX

Xxxxxxxxxxxx zahraničních xxxx,

xxxxxx xx xxxx x xxxxxxxx sdělení Ministerstva xxxxxxxxxxxx xxxx x. 58/2007 Xx. x. x. x č. 46/2008 Xx. x. x. x xxxxxxxxx xxxxxxx Xxxxxxxxxxxx zahraničních xxxx x. 98/2013 Xx. x. s. x Mezinárodní xxxxxx xxxxx dopingu ve xxxxxx

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx dne 11. xxxxxxxxx 2013 xxxx generální xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx znění Přílohy X - Xxxxxxx xxxxxxxxxx xxxxx a xxxxx - Xxxxxxxxxxx xxxxxxxx Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx.¹⁾

X xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx a prezident xxxxxxxxx xxxxxxxx xxxxxxx x přijetí xxxxx Xxxxxxx X Xxxxxx xxxxxxxxxx.

Xxxx znění Xxxxxxx X xxxxxxxxx x xxxxxxxx x xxxxxxx x xxxxxxx 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2014 x xxxxx xxxx vstoupilo x xxxxxxxx x xxx Xxxxxx republiku. Dnem xxxxxx xxxxxx xxxxx Xxxxxxx I x xxxxxxxx přestalo platit xxxxx Xxxxxxx X Xxxxxxxxxxx úmluvy xxxxx xxxxxxx ve xxxxxx xxxxxx xx 1. xxxxx 2013 a xxxxxxxxx xxx č. 98/2013 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X x xxxx xxxxxxx xx xxxxxxx jazyka xx vyhlašují současně.

¹⁾ Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx xxxxxxx dne 19. xxxxx 2005 x Xxxxxx xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.

XXXXXXXXXXX XXXXXX PROTI XXXXXXX XX XXXXXX
Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx - Xxxxxxxxxxx xxxxxxxx
Xxxxx, 1. ledna 2014

XXXXXX ZAKÁZANÝCH XXXXX X XXXXX DOPINGU XXX XXX 2014

XXXXXXX XXXXXXXXXXXXX KODEX

Platný xx 1. xxxxx 2014

Podle xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx skupin X1, X2, X4.4, X4.5 x S6(a) a Xxxxxxxxxx xxxxx M1, X2 x M3.

LÁTKY X XXXXXX ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX XXXXXX)

XXXXXXXX XXXXX

X0. XXXXXXXXXXX XXXXX

Xxxxxxxxx farmaceutická xxxxx, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx schválena xxx xxxxxxx xxxxxxxxxxxx xxxxxxx jakýmkoliv vládním xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. xxxxxx v xxxxxxxxxxxx xxxx klinickém xxxxxx xxxxxxx xxxx xx ukončené xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxx), je xxxxxxxx stále.

S1. XXXXXXXXXX XXXXX

Xxxxxxxxxx látky xxxx xxxxxxxx.

1. ANDROGENNÍ XXXXXXXXXX XXXXXXXX (XXX):

(x) Xxxxxxxx* XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-androst-1-en-3b,17β-diol); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx ([1,2]xxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-methyl-5α-androst-2-en-17β-ol); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-xxxxxx-4-xx-17α-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17β-xx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; methandriol; metasteron (17β-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx); methyldienolon (17β-hydroxy-17α-methylestra-4,9-dien-3-on); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); methyltestosteron; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9,11-trien-3-on); xxxxxxxxx; xxxxxxxxx; 19-norandrostendion (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; norklostebol; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4,:2,3]-5α-androstane); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx (17β-hyroxyestr-4,9,11-trien-3-on) x xxxxx xxxxx x podobnou chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

(b) Xxxxxxxxx** XXX, xxxxx jsou xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (androst-4-en-3,17-dion), dihydrotestosteron, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX), 3β-xxxxxxxxxxxxx-5-xx-17-xx), xxxxxxxxxxx x xxxxxx xxxxxxxxxx a xxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx:

5α-xxxxxxxxx-3α,17α-xxxx	5-xxxxxxxxxxxxx (androst-5-en-3,17-dion)
5α-androstan-3α,17β-diol	epi-dihydrotestosteron
5α-androstan-3β,17α-diol	epitestosteron
5α-androstan-3β,17β-diol	etiocholanolon
androst-4-en-3α,17α-diol	3α-hydroxy-5αandrostan-17-on
androst-4-en-3α,17β-diol	3β-hydroxy-5αandrostan-17-on
androst-5-en-3β,17α-diol	7α-hydroxy-DHEA
androst-5-en-3α,17α-diol	7β-hydroxy-DHEA
androst-5-en-3α,17β-dioI	7-keto-DHEA
androst-5-en-3β,17α-diol	19-norandrosteron
4-androstendiol (xxxxxxx-4-xx-3β,17β-xxxx)	19-xxxxxxxxxxxxxxxxx

Xxx xxxxx xxxxxxx xxxx xxxxx:

* "exogenní" xx vztahuje k xxxxx, xxxxxx tělo xxxxxxxx xxxxxxxxx neprodukuje.

** "xxxxxxxxx " se xxxxxxxx x xxxxx, xxxxxx xxxx normálně xxxxxxxxx xxxxxxxxx.

2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx androgenových xxxxxxxxx (SARM), tibolon, xxxxxxx, zilpaterol, xxx xx x xxxxxxxx xxxxx xx ně.

S2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX A PŘÍBUZNÉ XXXXX

Xxxxxxxxxxx xxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx:

1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (EPO), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx beta (XXXX), xxxxxxxxxxx /Xxxxxxxx/);

2. Xxxxxxxxxxxxxxxxxx (XX) x Xxxxxxxxxxxx hormon (XX) x xxxxxx xxxxxxxxxx xxxxxxx u xxxx;

3. Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxx;

4. Xxxxxxx xxxxxx (XX) x xxxx uvolňující xxxxxxx x insulinu xxxxxxx xxxxxxx faktor-1 (IGF-1).

Kromě xxxx xxxx xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxx:

Xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx), xxxxxxxxxxxx růstový xxxxxx (XXX), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), xxxxxxx xxxxxx odvozený x xxxxxxxx xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (VEGF), stejně xxxx xxxxxxxxx jiné xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx nebo xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxx, xxxxxx xxxxxxxx, využití energie, xxxxxxxxxxxxx xxxxxxxx nebo xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx;

x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

S3. BETA2- XXXXXXXX

Xxxxxxx beta-2 agonisté, xxxxxx všech xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. x- a x-), xxxx zakázáni kromě xxxxxxxxxxx xxxxxxxxxxx (xxxxxxxxx 1600 xxxxxxxxxx za 24 xxxxx), xxxxxxxxxxxx xxxxxxxxxxx (xxxxxxxxx podaná xxxxx 54 mikrogramů xx 24 hodin) x salmeterolu, pokud xxxx xxxxxx v xxxxxxxx x souladu x xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx vyšší xxx 1000 ng/ml x xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 40 xx/xx xxxxxx xxxxxxxxxx xx xxxxxxxxx terapeutické xxxxxxx, xxx xxxx xxxxxxxxxx za xxxxxxxxx xxxxxxxxxxx nález, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx výsledek xxx xxxxxxxx užíváním xxxxxxxxxxxx xxxxxxxxx xxxxx nižší xxx xxxx uvedené xxxxxxx.

X4. HORMONOVÉ X XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

1. Inhibitory aromatáz, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-androsten-3,6,17-trion (6-oxo), xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.

2. Selektivní xxxxxxxxxx estrogenových receptorů (XXXX), xxxxxxxxxx:

Xxxxxxxxx, tamoxifen, xxxxxxxxx, xxx ne x xxxxxxxx pouze xx ně.

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx zahrnující:

Cyklofenil, xxxxxxxxxxx, klomifen, xxx xx x omezením xxxxx na ně.

4. Xxxxx xxxxxxxxxxxx funkce xxxxxxxxxx včetně inhibitorů xxxxxxxxxx, ale ne x omezením xxxxx xx xx.

5. Xxxxxxxxxxx xxxxxxxxxx:

x) Insuliny;

b) Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (XXXXδ) xxxxxxxx/ (xxxx. XX 1516) a Xxxxxxxx proteinkinasové osy xxxxxxxxxx XXX v xxxxxxxxxxx x XXXX xxxxx /PPARδ-AMP-activated protein xxxxxx (AMPK) axis xxxxxxxx/ (xxxx. AICAR)

S5. XXXXXXXXX X OSTATNÍ XXXXXXXXX LÁTKY

Maskovací xxxxx xxxx xxxxxxxx. Zahrnují:

Diuretika, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (např. xxxxxxxx, xxxxxxxxxx podání xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx. Lokální xxxxxx xxxxxxxxxxxx pro zubní xxxxxxxx xxxx xxxxxxxx.

Xxxxxxxxx xxxxxxxx:

Xxxxxxxxxxxx, xxxxxxxx, bumetanid, xxxxxxxxx, chlortalidon, xxxxxxxxx, xxxxxxxx, xxxxxxxx etakrynová, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), triamteren, xxxxxxx (xxxx. tolvaptan) a xxxxx látky s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx drospirenonu, xxxxxxxxx x xxxxxxxxx xxxxxx dorzolamidu a xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).

Xxx xxxxxxx (Xxx Xxxxxxx, xxxxxxxx Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx xxxxx se xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx spojení x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx xx xxxxxxxxxx udělení xxxxxxxxxx Terapeutické xxxxxxx xx xxxx xxxxx xxxxx x xx, xxxxx xxx byla xxxxxxx na xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX METODY

M1. XXXXXXXXXX X XXXX X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxx xxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, alogenní (homologní) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx x xxx xxxxxxxxx xxxxxxxx jakéhokoliv xxxxxx xx xxxxxxxxx xxxxxxx.

2. Xxxxx zvyšování xxxxxxxx, xxxxxxx nebo dodávky xxxxxxx, zahrnující xxxxxxxxxxxx xxxxxxxxxxxxx produkty (např. xxxxxx náhražky xxxxxxxx xx xxxxxxxxxxx, mikroenkapsulované xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx a xxxxxxxxxxx (XXX13), xxx xx x omezením xxxxx xx xx. Xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxx.

3. Xxxxxxxxx forma xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx nebo x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx xxxxx x xxxxxx, za xxxxxx porušit xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Dopingové xxxxxxxx. Xx xxxxxxxx xxxxxx a/nebo xxxxxx (xxxx. proteázami) xxxx, xxx xx x xxxxxxxx pouze xx xx.

2. Nitrožilní infuze x/xxxx xxxxxxx více xxx 50 ml xx 6 xxxxx xxxxx infuzí xxxxxxxxx xxxxxxxxx x průběhu xxxxxxxxxxxx zákroků nebo xxxxxxxxxx vyšetřovacích xxxxx.

X3. XXXXXX DOPING

Z důvodu xxxxxxxxxx xx zvýšení xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:

1. Transfer xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx;

2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx buněk.

LÁTKY X METODY XXXXXXXX XXX XXXXXXX

Xxxxx xxxxxxxxx X0 až X5 x X1 až X3 xxxxxxxxx výše xxxx Při Xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx:

XXXXXXXX XXXXX

X6. STIMULANCIA

Všechna xxxxxxxxxxx xxxxxx xxxxx xxxxxx případných xxxxxxxxx xxxxxxx (xxxx. x- x x-) jsou xxxxxxxx, x xxxxxxxx xxxxxxxx imidazoiu v xxxxxxx jejich xxxxxxxx xxxxxxx x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2014*.

Xxxxxxxxxxx xxxxxxxx:

(x) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx, xxxxxxxxxx, amfetamin, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxx, bromantan, xxxxxxxxxxxxx, xxxxxxxxx, fenfluramin, fenkamin, xxxxxxxxxxx, xxxxxxxxxxx, fentermin, xxxxxxxxxxxx /4-fenylpiracetam (karfedon)/, xxxxxxxxxx, klobenzorex, kokain, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (d-), xxxxxxxx, modafinil, norfenfluramin, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx není výslovně xxxxxxx x xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx xxxxxxxxxxx (xxxxxxxx):

Xxxxxxxxx (epinefrin)****, xxxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxx***, xxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxx), xxxxxxxxxxxx, xxxxx**, katinon x xxxx xxxxxxx (xxxx. xxxxxxxx, xxxxxxxxx, xxxx-xxxxxxxxxxxxxxxxxxxxx), xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx***, xxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxx (dimetylpentylamin), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxx), xxxxxxx, pentetrazol, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx), trimetazidin, xxxxxxxxxxxxx x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

* Xxxxxxxxxxx xxxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2014 (xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, xxxxxx, xxxxxxx, pipradrol, xxxxxxxx) xxxxxx xxxxxxxxxx xx Xxxxxxxx látky.

** Xxxxx xx xxxxxxxx xxxxx při koncentraci xxxxx než 5 xxxxxxxxxx v 1 xx xxxx.

*** Xxxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx moči.

**** Xxxxxxx xxxxxx xxxxxxxxxx (xxxxxxxxxx) (xxxx. xxxxx, xxxx xxxxxxxx) nebo xxxx xxxxxx xxxxxxxx s xxxxxxxxx anestetiky xxxx xxxxxxxx.

***** Pseudoefedrin xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx v xxxx xx xxxxx xxx 150 xxxxxxxxxx xx xxxxxxxx.

X7. NARKOTIKA

Zakázané xx xxxxxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxxx, diamorfin(heroin), xxxxxxxx x jeho xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.

X8. KANABINOIDY

Přírodní (xxxx. xxxxx, xxxxxx x xxxxxxxxx) xxxx xxxxxxxxxx delta9-tetrahydrokanabinol (XXX) x kanabimimetika (xxxx. "Xxxxx", JWH018, XXX073 x XX-210) jsou xxxxxxxx.

X9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.

XXXXX XXXXXXXX X XXXXXXXX XXXXXXXX

X1. XXXXXXX

Xxxxxxx (etanol) xx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Detekce xx bude provádět xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx xxxx. Xxxxxxx xxxxxxx xxx xxxxxxxx xxxxxxxxxxx pravidla xx xxxxxxxxxxxx koncentrací alkoholu x krvi 0.10 x/x.

• Xxxxxxxxxxxx xxxxx (XXX)

• Xxxxxx (XXX)

• Xxxxxxx xxxxxx x xxxxxxxxxxxx (FAI)

• Xxxxxxxxxxx (XX)

• Xxxxxxxxxxx xxxxx (XXX)

• Xxxxx motorismus (XXX)

X2. XXXX-XXXXXXXXX

Xxxxx xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx pouze Xxx Xxxxxxx v xxxxxxxxxxxxx xxxxxxxx.

• Xxxxxxxxxxxx xxxxx (XXX)

• Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)

• Xxxx (IGF)

• Xxxxxxxxxxx (XX) (xxxxxxxx také Xxxx xxxxxx)

• Lyžování (XXX) - skoky xx lyžích x xxxxxxxxxxx xxxxxxxx-xxxxx a X-xxxxx, x xxxxxxxxx X-xxxxx x "big xxx"

• Xxxxxxx (XXXX, XXX) (zakázané xxxx Xxxx xxxxxx)

• Šipky (XXX)

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx, xxxxxxxxxx, atenolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxx, karteolol, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, pindolol, propranolol, xxxxxxx, xxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.

Informace

Právní předpis č. 47/2014 Sb. m. x. xxxxx xxxxxxxxx xxxx 20.9.2014.

Xxxxxx předpis x. 47/2014 Xx. x. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 19/2017 Sb. m. s. x účinností xx 6.4.2017.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx předpisů x xxxxxxxx xxxx aktualizováno, xxxxx xx xxxx xxxxxx derogační změna xxxxx uvedeného xxxxxxxx xxxxxxxx.